Skip to content
Decision-ready map
• Start with the harm: prevent burns and pigment injury
• Map the mechanism: melanin absorption + protocol settings → heating
• Choose intervention: safer protocols, better guardrails, or better evidence
• Validate early: stratified safety outcomes across skin tones
(1) What it is
If you are early in the innovation journey, light-based therapy is a valuable case where physics, protocol design, and user behavior intersect. The core issue is straightforward: when a protocol deposits too much energy in tissue, heat rises and can cause injury. Because melanin is an absorber for many visible/NIR wavelengths, the same nominal settings can produce different thermal responses across skin tones. “Equity-by-design” here means building and proving safety across the population you intend to serve, not adding warnings after harm occurs.
(2) Who it helps
This brief helps innovators deciding what to build: a device, a clinic protocol package, a monitoring/guardrail layer (e.g., temperature sensing + stop rules), a training program, or a procurement and quality tool. It is designed for the pre-regulatory stage where framing the first safe use case matters more than maximizing claims.
(3) What evidence exists
Evidence signals that differential risk is real. A 2025 cohort study observed substantially higher odds of clinically visible thermal injury in darker skin during a dual-wavelength low-power laser protocol (https://doi.org/10.1111/phpp.70042). Dermatology reviews on skin of color emphasize that parameter selection and technique strongly influence complication risk (https://doi.org/10.4103/ijdvl.IJDVL_88_17), and IPL complication reviews catalog burns and pigmentary changes tied to settings (https://doi.org/10.1002/der2.57). PBM dosimetry literature highlights that incomplete specification of “dose” makes safety claims unreliable (https://doi.org/10.21037/atm.2016.05.34). FDA draft guidance on PBM devices signals what “credible evaluation and labeling” looks like once a product moves toward medical claims (FDA webpage).
(4) Translation barriers
Early innovators often face: (i) ‘one setting fits all’ assumptions; (ii) unclear parameter definitions (power without spot size or duty cycle); (iii) weak feedback loops (minor burns/pigment changes not captured); and (iv) premature claim inflation (jumping to medical benefits without safety stratification). Another common barrier is confusing skin tone with Fitzpatrick phototype; they are related but not interchangeable for optical absorption.
(5) Equity/safety checks
Pick a low-risk first deployment. If your idea changes settings automatically or enables home use, safety guardrails become essential: conservative defaults, guided titration, mandatory stop rules for heat/pain, and (ideally) sensing (temperature, contact, distance) that can trigger auto-stop. Treat stratified adverse-event reporting (by skin tone/phototype) as a minimum deliverable. If you cannot run a full clinical study yet, build evidence with a staged approach: bench thermal testing + supervised pilots + careful incident reporting.
(6) Decision questions
• What is your first “safe” use case: supervised clinic decision support, protocol standardization, or a device feature that reduces overheating risk?
• Can you specify dose fully (wavelength, irradiance at skin, spot size, duty cycle, time, cooling) so others can reproduce safety?
• How will you measure and report subgroup safety outcomes across skin tones?
• What is your stop rule and escalation pathway when discomfort or skin change occurs?
(7) Practical next steps
1) Write a one-page translation hypothesis: harm pathway (overheating) → intervention point (protocol, device guardrail, training).
2) Define a complete parameter schema and enforce it in every pilot log.
3) Build an incident reporting loop (including delayed pigment changes) and review it stratified by skin tone/phototype.
4) Use FDA PBM guidance as a roadmap for what evidence and labeling will be required if you move toward medical device claims.
(8) References
https://doi.org/10.1111/phpp.70042
https://doi.org/10.4103/ijdvl.IJDVL_88_17
https://doi.org/10.1002/der2.57
https://doi.org/10.21037/atm.2016.05.34
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premark-notification-510k-submissions